The company's leading drug candidate, lorcaserin hydrochloride, has received positive clinical trial data and is marketed in the U.S. and South Korea under the brand name Belviq for weight management. Arena Pharmaceuticals collaborates with Eisai to market Belviq in other countries and has a presence in Europe through its Swiss subsidiary, Arena GmbH. The company's pipeline includes drugs for autoimmune, vascular, and thrombotic diseases, as well as dementia-associated psychosis, nervous system issues, and pain. Arena Pharmaceuticals is now part of Pfizer.